Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to § 35a Social Code Book V
Report documents
-
Extract of dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to § 35a Social Code Book V
-
Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to § 35a Social Code Book V
Dossier assessment
Adults and adolescents, aged 12 years and older and weighing at least 40 kg, with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
- Patients ≥ 18 years: hint of considerable added benefit
- Patients ≥ 12 to < 18 years: added benefit not proven
Project details
- Project no.
- A22-111
- Commission
- Commission awarded on 17.10.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed